These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Trophic cascades following the disease-induced decline of an apex predator, the Tasmanian devil. Hollings T; Jones M; Mooney N; McCallum H Conserv Biol; 2014 Feb; 28(1):63-75. PubMed ID: 24024987 [TBL] [Abstract][Full Text] [Related]
4. Molecular characterization of Cryptosporidium and Giardia from the Tasmanian devil (Sarcophilus harrisii). Wait LF; Fox S; Peck S; Power ML PLoS One; 2017; 12(4):e0174994. PubMed ID: 28423030 [TBL] [Abstract][Full Text] [Related]
5. Evidence for induction of humoral and cytotoxic immune responses against devil facial tumor disease cells in Tasmanian devils (Sarcophilus harrisii) immunized with killed cell preparations. Kreiss A; Brown GK; Tovar C; Lyons AB; Woods GM Vaccine; 2015 Jun; 33(26):3016-25. PubMed ID: 25708088 [TBL] [Abstract][Full Text] [Related]
6. Doxorubicin and carboplatin trials in Tasmanian devils (Sarcophilus harrisii) with Tasmanian devil facial tumor disease. Phalen DN; Frimberger AE; Peck S; Pyecroft S; Harmsen C; Lola S; Moore AS Vet J; 2015 Dec; 206(3):312-6. PubMed ID: 26538144 [TBL] [Abstract][Full Text] [Related]
7. Development of a SNP-based assay for measuring genetic diversity in the Tasmanian devil insurance population. Wright B; Morris K; Grueber CE; Willet CE; Gooley R; Hogg CJ; O'Meally D; Hamede R; Jones M; Wade C; Belov K BMC Genomics; 2015 Oct; 16():791. PubMed ID: 26467759 [TBL] [Abstract][Full Text] [Related]
8. Density trends and demographic signals uncover the long-term impact of transmissible cancer in Tasmanian devils. Lazenby BT; Tobler MW; Brown WE; Hawkins CE; Hocking GJ; Hume F; Huxtable S; Iles P; Jones ME; Lawrence C; Thalmann S; Wise P; Williams H; Fox S; Pemberton D J Appl Ecol; 2018 May; 55(3):1368-1379. PubMed ID: 30089931 [TBL] [Abstract][Full Text] [Related]
9. Individual and temporal variation in pathogen load predicts long-term impacts of an emerging infectious disease. Wells K; Hamede RK; Jones ME; Hohenlohe PA; Storfer A; McCallum HI Ecology; 2019 Mar; 100(3):e02613. PubMed ID: 30636287 [TBL] [Abstract][Full Text] [Related]
10. High blood lead concentrations in captive Tasmanian devils (Sarcophilus harrisii): a threat to the conservation of the species? Hivert LG; Clarke JR; Peck SJ; Lawrence C; Brown WE; Huxtable SJ; Schaap D; Pemberton D; Grueber CE Aust Vet J; 2018 Nov; 96(11):442-449. PubMed ID: 30370598 [TBL] [Abstract][Full Text] [Related]
11. Curse of the devil: molecular insights into the emergence of transmissible cancers in the Tasmanian devil (Sarcophilus harrisii). Patchett AL; Flies AS; Lyons AB; Woods GM Cell Mol Life Sci; 2020 Jul; 77(13):2507-2525. PubMed ID: 31900624 [TBL] [Abstract][Full Text] [Related]
12. Reduced effect of Tasmanian devil facial tumor disease at the disease front. Hamede R; Lachish S; Belov K; Woods G; Kreiss A; Pearse AM; Lazenby B; Jones M; McCallum H Conserv Biol; 2012 Feb; 26(1):124-34. PubMed ID: 21978020 [TBL] [Abstract][Full Text] [Related]
13. Demonstration of immune responses against devil facial tumour disease in wild Tasmanian devils. Pye R; Hamede R; Siddle HV; Caldwell A; Knowles GW; Swift K; Kreiss A; Jones ME; Lyons AB; Woods GM Biol Lett; 2016 Oct; 12(10):. PubMed ID: 28120799 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of selective culling of infected individuals to control tasmanian devil facial tumor disease. Lachish S; McCallum H; Mann D; Pukk CE; Jones ME Conserv Biol; 2010 Jun; 24(3):841-51. PubMed ID: 20088958 [TBL] [Abstract][Full Text] [Related]
15. Season, weight, and age, but not transmissible cancer, affect tick loads in the endangered Tasmanian devil. Belkhir S; Hamede R; Thomas F; Ujvari B; Dujon AM Infect Genet Evol; 2022 Mar; 98():105221. PubMed ID: 35065301 [TBL] [Abstract][Full Text] [Related]
16. Immunization Strategies Producing a Humoral IgG Immune Response against Devil Facial Tumor Disease in the Majority of Tasmanian Devils Destined for Wild Release. Pye R; Patchett A; McLennan E; Thomson R; Carver S; Fox S; Pemberton D; Kreiss A; Baz Morelli A; Silva A; Pearse MJ; Corcoran LM; Belov K; Hogg CJ; Woods GM; Lyons AB Front Immunol; 2018; 9():259. PubMed ID: 29515577 [TBL] [Abstract][Full Text] [Related]
17. Discovery of Biomarkers for Tasmanian Devil Cancer (DFTD) by Metabolic Profiling of Serum. Karu N; Wilson R; Hamede R; Jones M; Woods GM; Hilder EF; Shellie RA J Proteome Res; 2016 Oct; 15(10):3827-3840. PubMed ID: 27599268 [TBL] [Abstract][Full Text] [Related]
18. Isotopic niche variation in Tasmanian devils Bell O; Jones ME; Cunningham CX; Ruiz-Aravena M; Hamilton DG; Comte S; Hamede RK; Bearhop S; McDonald RA Ecol Evol; 2021 Jun; 11(12):8038-8053. PubMed ID: 34188870 [TBL] [Abstract][Full Text] [Related]
19. Hematologic and serum biochemical changes associated with Devil Facial Tumor Disease in Tasmanian Devils. Peck S; Corkrey R; Hamede R; Jones M; Canfield P Vet Clin Pathol; 2016 Sep; 45(3):417-29. PubMed ID: 27589840 [TBL] [Abstract][Full Text] [Related]
20. Evolution in a transmissible cancer: a study of the chromosomal changes in devil facial tumor (DFT) as it spreads through the wild Tasmanian devil population. Pearse AM; Swift K; Hodson P; Hua B; McCallum H; Pyecroft S; Taylor R; Eldridge MD; Belov K Cancer Genet; 2012 Mar; 205(3):101-12. PubMed ID: 22469509 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]